Skip to main content
Evan Dellon, MD, Gastroenterology, Chapel Hill, NC, University of North Carolina Hospitals

EvanS.DellonMD

Gastroenterology Chapel Hill, NC

Advanced Endoscopic Interventional

Assistant Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Dr. Dellon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Dellon's full profile

Already have an account?

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Gastroenterology, 2004 - 2007
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1999

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2004 - 2024
  • MA State Medical License
    MA State Medical License 2001 - 2004
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis  
    Evan S Dellon, Kathryn A Peterson, Gary W Falk, Nirmala Gonsalves, Michael Vaezi, Adam C Bledsoe, Alan T Chang, Ikuo Hirano, The New England Journal of Medicine
  • RPC4046 in Patients with Eosinophilic Esophagitis  
    Evan S Dellon, Ikuo Hirano, Clinical Gastroenterology and Hepatology

Lectures

  • Eosinophilic Esophagitis 
    American Gastroenterological Association (AGA) Institute, Coronado, California - 1/17/2013
  • Eosinophilic Disorders of the GI Tract 
    AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/6/2018

Authored Content

  • RPC4046 in Patients with Eosinophilic EsophagitisMarch 2020

Press Mentions

  • VIDEO: Mepolizumab for EoE Does Not Yield ‘Prominent Symptom Improvement’ After 6 Months
    VIDEO: Mepolizumab for EoE Does Not Yield ‘Prominent Symptom Improvement’ After 6 MonthsMay 11th, 2023
  • 15 Silent Signs Your Body Might Be in Big Trouble
    15 Silent Signs Your Body Might Be in Big TroubleJanuary 5th, 2023
  • Dupilumab Effective for Eosinophilic Esophagitis up to 52 Weeks
    Dupilumab Effective for Eosinophilic Esophagitis up to 52 WeeksDecember 28th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations